322 related articles for article (PubMed ID: 2446734)
1. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma.
Panza N; Pacilio G; Campanella L; Peluso G; Battista C; Amoriello A; Utech W; Vacca C; Lombardi G
Cancer; 1988 Jan; 61(1):76-83. PubMed ID: 2446734
[TBL] [Abstract][Full Text] [Related]
2. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.
Carpelan-Holmström M; Haglund C; Lundin J; Alfthan H; Stenman UH; Roberts PJ
Br J Cancer; 1996 Sep; 74(6):925-9. PubMed ID: 8826859
[TBL] [Abstract][Full Text] [Related]
3. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
4. CA 125, CA 15.3, CA 27.29, CEA, beta-hCG and alpha-fetoprotein levels in cyst fluid of breast macrocysts.
Martínez L; Castilla JA; Blanco N; Perán F; Herruzo A
Int J Gynaecol Obstet; 1995 Feb; 48(2):187-92. PubMed ID: 7540567
[TBL] [Abstract][Full Text] [Related]
5. Combination assay of CA125, TPA, IAP, CEA, and ferritin in serum for ovarian cancer.
Yabushita H; Masuda T; Ogawa A; Noguchi M; Ishihara M
Gynecol Oncol; 1988 Jan; 29(1):66-75. PubMed ID: 3422208
[TBL] [Abstract][Full Text] [Related]
6. Tumor markers in the ovarian carcinoma.
Margariti PA; Benedetti Panici P; Villani L; Di Roberto P; Maiorca A; Sacco F; Bompiani A
Eur J Gynaecol Oncol; 1980 May; 1(2):77-9. PubMed ID: 6174341
[No Abstract] [Full Text] [Related]
7. Serum levels of six tumor markers in patients with benign and malignant gynecological disease.
Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sato T; Takamizawa H; Wiklund B
Arch Gynecol Obstet; 1988; 243(2):61-8. PubMed ID: 3401042
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
Purnell DM; Heatfield BM; Trump BF
Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
Alvarez JA; Marín J; Jover JM; Fernández R; Fradejas J; Moreno M
Dis Colon Rectum; 1995 May; 38(5):535-42. PubMed ID: 7537651
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical evaluation of human esophageal neoplasms and preneoplastic lesions for beta-chorionic gonadotropin, placental lactogen, alpha-fetoprotein, carcinoembryonic antigen, and nonspecific cross-reacting antigen.
Burg-Kurland CL; Purnell DM; Combs JW; Hillman EA; Harris CC; Trump BF
Cancer Res; 1986 Jun; 46(6):2936-43. PubMed ID: 2421889
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis.
Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Kiviranta A; Hallman K; Holm L; Weiner E; Tamsen L
Gynecol Oncol; 1990 Oct; 39(1):16-25. PubMed ID: 2227569
[TBL] [Abstract][Full Text] [Related]
12. Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sekiya S; Takamizawa H; Suzuki N; Tokita H
Arch Gynecol Obstet; 1988; 243(2):69-81. PubMed ID: 3165255
[TBL] [Abstract][Full Text] [Related]
13. Oncofetal antigens in ovarian cyst fluids.
Kraly DH; Koh SH; Hay DL; Cauchi MN
Gynecol Obstet Invest; 1984; 18(3):117-21. PubMed ID: 6208091
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease.
Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Tamsen L
Gynecol Oncol; 1990 Oct; 39(1):26-33. PubMed ID: 2227570
[TBL] [Abstract][Full Text] [Related]
15. [New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary].
Indraccolo SR; Cecchi A; Thodos A; Brandi S; Carta G
Ann Ostet Ginecol Med Perinat; 1991; 112(1):36-40. PubMed ID: 1929097
[TBL] [Abstract][Full Text] [Related]
16. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors.
Inoue M; Fujita M; Nakazawa A; Ogawa H; Tanizawa O
Obstet Gynecol; 1992 Mar; 79(3):434-40. PubMed ID: 1346716
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the tumor markers CEA, TPA, and CA 19-9 in colorectal carcinoma.
Putzki H; Student A; Jablonski M; Heymann H
Cancer; 1987 Jan; 59(2):223-6. PubMed ID: 3467817
[TBL] [Abstract][Full Text] [Related]
18. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
19. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9.
Buccheri GF; Ferrigno D; Sartoris AM; Violante B; Vola F; Curcio A
Cancer; 1987 Jul; 60(1):42-50. PubMed ID: 3472637
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of tumor markers and their clinical significance in epithelial ovarian cancer.
Shan D; Cheng S; Ma Y; Peng H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jul; 48(7):1039-1049. PubMed ID: 37724407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
